CeriBell, Inc.

CeriBell, Inc.

NNASDAQ:CBLL
26.42
USD
+0.28
(+1.07%)
-1.95EPS
946.84MMarket Cap
Mar 02Next Earn
CeriBell, Inc.
NASDAQ:CBLL
(Nasdaq Stock Market)

Recent

price

26.42

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
TTM
USD
1.11
1.94
5.48
2.44
2.87
Revenue per Share
-1.59
-1.26
-3.39
-1.46
-1.95
Basic EPS, GAAP
-1.39
-1.29
-3.04
-1.14
-1.51
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
-2.54
-3.3
5.33
4.14
3.03
Book Value per Share
-2.54
-3.3
5.33
4.14
3.03
Tangible Book Value per Share
23
23
12
37
38
Basic Weighted Avg Shares
26
45
65
89
109
Sales/Revenue/Turnover
-138.96
-66.43
-60.68
-65.57
-69.79
Operating Margin (%)
- -
1
1
1
1
Depreciation Expense
-37
-29
-40
-53
-74
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-143.37
-65.15
-61.82
-59.97
-67.96
Profit Margin (%)
70
30
204
168
129
Working Capital
15
2
21
21
20
LT Debt
-86
-112
191
155
118
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-30.84
-52.47
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
1
1
LT Borrowings
20
20
20
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
38
38
39
Market Capitalization
694
743
947

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
169
158
147
Cash, Cash Equivalents & STI
141
129
117
Accounts Receivable, Net
16
16
18
Inventories
7
7
7
Total Current Liabilities
16
17
18
Payables & Accruals
12
10
10
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-18.74%
Free Cash Flow
- -
- -
14.27%
Net Income, GAAP
- -
- -
32.03%
Sales/Revenue/Turnover
- -
- -
36.09%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
14
15
17
19
65
2025
20
21
23
25
89
2026
26
28
29
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.25
-0.26
-0.31
-0.4
-3.39
2025
-0.36
-0.38
-0.37
-0.36
-1.46
2026
-0.52
-0.51
-0.55
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
CeriBell, Inc. (Nasdaq: CBLL) develops and commercializes the Ceribell System, a point-of-care electroencephalography (EEG) platform that combines portable hardware and artificial intelligence-powered algorithms for rapid diagnosis and continuous monitoring of patients at risk of seizures in acute care settings across the United States. The system comprises disposable headbands with ten non-invasive electrodes pre-filled with conductive gel; pocket-sized, battery-operated recorders that capture and wirelessly transmit EEG signals; Clarity, an AI-powered seizure detection algorithm providing real-time alerts for electrographic status epilepticus; and the Ceribell EEG Portal, a cloud-based platform enabling remote access to EEG data, signal quality comparable to conventional EEG, and seizure burden trending for clinicians. Founded in 2014 and headquartered in Sunnyvale, California, the company targets hospitals including ICUs, emergency departments, and VA systems, serving over 615 active accounts as of September 2025 with a focus on improving patient outcomes such as shorter ICU stays and better neurological recovery. Recent developments include its initial public offering in October 2024, raising $180.3 million at $17 per share; FDA 510(k) clearance in November 2025 for the next-generation Clarity algorithm; expanded Clarity clearance for neonates, preterm and up, marking the broadest age range for seizure detection; and FedRAMP high authorization in Q2 2025, unlocking access to nearly 200 VA hospitals; alongside Q3 2025 revenue of $22.6 million, up 31% year-over-year.

Company News

  • CeriBell, Inc. (CBLL) Reports Q3 Loss, Tops Revenue Estimates

  • CeriBell, Inc. (CBLL) Q3 2026 Earnings Call Transcript

  • Compared to Estimates, CeriBell, Inc. (CBLL) Q3 Earnings: A Look at Key Metrics

  • CeriBell Q3 Earnings Call Highlights

  • Ceribell Reports Third Quarter 2026 Financial Results

  • Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution

  • Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

  • Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026

  • Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

  • BlackRock Inc. Acquires New Holdings in CeriBell, Inc. $CBLL

  • Bank of America Corp DE Has $5.86 Million Position in CeriBell, Inc. $CBLL

  • CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push

  • CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript

  • Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings

  • CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates

  • CeriBell Q2 Earnings Call Highlights

  • Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review

  • Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System

  • Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O'Keefe

  • Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference